Therapeutic Drug Monitoring (TDM)

Therapeutic Drug Monitoring (TDM) aims to optimize biologic treatment for an individual patient. AFIAS can detect drug concentration and/or anti-drug antibodies against drugs, using a small amount of human serum or whole blood, and providing results in just 10-22 minutes. This enables physicians to verify the presence of anti-drug antibodies immediately before the next administration.

Many biological drugs can induce an immunogenic response, where antibodies against a drug can have negative effects such as secondary treatment failure.

The test utilizes a bridging immunoassay to detect antibodies to specific drugs (X). Anti-X antibodies from the sample are bridged with fluorescence and biotin-labeled drug X, forming immune complexes, migrating onto a nitrocellulose matrix to be captured by immobilized streptavidin on a test strip. Higher levels of antibodies to a specific drug X in the sample will form more immune complexes, leading to a stronger fluorescence signal processed by the instrument for AFIAS tests to show free anti-X concentration.

• Sample types: Whole blood, Serum, Plasma
• Fast reaction Time: 10-22 mins
• Detection Range: 0.2-200 AU/mL
• Intended Use: Semi-quantitative determination of antibodies against adalimumab in human whole blood/serum

Our Kits

• Free Anti-Adalimumab
• Free Anti-Etanercept
• Free Anti-Golimumab
• Free Anti-Infliximab
• Free Anti-Trastuzumab
• Free Anti-Ustekinumab
• Free Anti-Vedolizumab
• Golimumab
• Infliximab
• Total Anti-Infliximab
• Trastuzumab
• Ustekinumab
• Vedolizumab